gamma-aminobutyric acid has been researched along with Child Mental Disorders in 14 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 8.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 4.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "Medical history interviews, seizure surveys, Vineland Adaptive Behavior Scales Second Edition and other behavioural surveys were completed by primary care givers of 28 participants in Simons Searchlight." | 1.72 | Neurodevelopmental phenotypes associated with pathogenic variants in ( Brooks, E; Chung, W; Geltzeiler, A; Green Snyder, L; Kahen, A; Kavus, H; Kentros, C; Taylor, C, 2022) |
| "We performed EEG recordings and autism diagnostic interview." | 1.56 | Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism. ( Cai, K; Delpire, E; Eissman, J; Flamm, C; Kang, JQ; Li, BM; Li, ZY; Liao, WP; Mermer, F; Nwosu, G; Poliquin, S; Shen, W; Shi, YW; Wang, J; Xu, D, 2020) |
| " We develop a system in human pluripotent stem cells (hPSCs) using CRISPR/Cas9 and SMASh technology, with which we can target endogenous proteins for precise dosage control in hPSCs and at multiple stages of neural differentiation." | 1.51 | Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1 syndrome. ( Hu, B; Li, M; Li, W; Mi, T; Mo, F; Teng, Z; Wu, Y; Zhang, B; Zhou, Q; Zhu, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 11 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ahring, PK | 1 |
| Liao, VWY | 1 |
| Gardella, E | 1 |
| Johannesen, KM | 1 |
| Krey, I | 1 |
| Selmer, KK | 1 |
| Stadheim, BF | 1 |
| Davis, H | 1 |
| Peinhardt, C | 1 |
| Koko, M | 1 |
| Coorg, RK | 1 |
| Syrbe, S | 1 |
| Bertsche, A | 1 |
| Santiago-Sim, T | 1 |
| Diemer, T | 1 |
| Fenger, CD | 1 |
| Platzer, K | 2 |
| Eichler, EE | 1 |
| Lerche, H | 1 |
| Lemke, JR | 1 |
| Chebib, M | 1 |
| Møller, RS | 1 |
| Lüffe, TM | 1 |
| D'Orazio, A | 1 |
| Bauer, M | 1 |
| Gioga, Z | 1 |
| Schoeffler, V | 1 |
| Lesch, KP | 1 |
| Romanos, M | 1 |
| Drepper, C | 1 |
| Lillesaar, C | 1 |
| Chen, W | 1 |
| Ge, Y | 1 |
| Lu, J | 1 |
| Melo, J | 1 |
| So, YW | 1 |
| Juneja, R | 1 |
| Liu, L | 1 |
| Wang, YT | 1 |
| Cediel, ML | 1 |
| Stawarski, M | 1 |
| Blanc, X | 1 |
| Nosková, L | 1 |
| Magner, M | 1 |
| Gburek-Augustat, J | 1 |
| Baldridge, D | 1 |
| Constantino, JN | 1 |
| Ranza, E | 1 |
| Bettler, B | 1 |
| Antonarakis, SE | 1 |
| Pang, EW | 1 |
| Hammill, C | 1 |
| Taylor, MJ | 1 |
| Near, J | 1 |
| Schachar, R | 1 |
| Crosbie, J | 1 |
| Arnold, PD | 1 |
| Anagnostou, E | 1 |
| Lerch, JP | 1 |
| van van Hugte, EJH | 1 |
| Schubert, D | 1 |
| Nadif Kasri, N | 1 |
| Wang, J | 2 |
| Poliquin, S | 2 |
| Mermer, F | 2 |
| Eissman, J | 1 |
| Delpire, E | 1 |
| Shen, W | 2 |
| Cai, K | 1 |
| Li, BM | 1 |
| Li, ZY | 1 |
| Xu, D | 1 |
| Nwosu, G | 2 |
| Flamm, C | 1 |
| Liao, WP | 1 |
| Shi, YW | 1 |
| Kang, JQ | 2 |
| Sprengers, JJ | 1 |
| van Andel, DM | 1 |
| Bruining, H | 1 |
| Tang, X | 1 |
| Jaenisch, R | 1 |
| Sur, M | 1 |
| Kahen, A | 1 |
| Kavus, H | 1 |
| Geltzeiler, A | 1 |
| Kentros, C | 1 |
| Taylor, C | 1 |
| Brooks, E | 1 |
| Green Snyder, L | 1 |
| Chung, W | 1 |
| Rigsby, K | 1 |
| Rastogi, A | 1 |
| Romero-Morales, A | 1 |
| McGrath, P | 1 |
| Demerast, S | 1 |
| Aoto, J | 1 |
| Bilousova, G | 1 |
| Lal, D | 1 |
| Gama, V | 1 |
| Benke, D | 1 |
| Möhler, H | 1 |
| Li, S | 1 |
| Kumar T, P | 1 |
| Joshee, S | 1 |
| Kirschstein, T | 1 |
| Subburaju, S | 1 |
| Khalili, JS | 1 |
| Kloepper, J | 1 |
| Du, C | 1 |
| Elkhal, A | 1 |
| Szabó, G | 1 |
| Jain, RK | 1 |
| Köhling, R | 1 |
| Vasudevan, A | 1 |
| Zhu, W | 1 |
| Zhang, B | 1 |
| Li, M | 1 |
| Mo, F | 1 |
| Mi, T | 1 |
| Wu, Y | 1 |
| Teng, Z | 1 |
| Zhou, Q | 1 |
| Li, W | 1 |
| Hu, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gamma-aminobutyric acid and Child Mental Disorders
| Article | Year |
|---|---|
Excitatory/inhibitory balance in epilepsies and neurodevelopmental disorders: Depolarizing γ-aminobutyric acid as a common mechanism.
Topics: Epilepsy; gamma-Aminobutyric Acid; Humans; Neurodevelopmental Disorders; Seizures | 2023 |
The role of GABAergic signalling in neurodevelopmental disorders.
Topics: GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Nerve Net; Neurodevelopmental Disorders; Precisi | 2021 |
Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Neurodevelopmental Disorders | 2018 |
11 other studies available for gamma-aminobutyric acid and Child Mental Disorders
| Article | Year |
|---|---|
Gain-of-function variants in GABRD reveal a novel pathway for neurodevelopmental disorders and epilepsy.
Topics: Autism Spectrum Disorder; Epilepsy; Epilepsy, Generalized; GABA Plasma Membrane Transport Proteins; | 2022 |
Increased locomotor activity via regulation of GABAergic signalling in foxp2 mutant zebrafish-implications for neurodevelopmental disorders.
Topics: Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Locomotion; Neurodevelopmental Disorders; Zebra | 2021 |
Distinct Functional Alterations and Therapeutic Options of Two Pathological De Novo Variants of the T292 Residue of GABRA1 Identified in Children with Epileptic Encephalopathy and Neurodevelopmental Disorders.
Topics: Animals; Child; Epilepsy; Epilepsy, Generalized; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Muta | 2022 |
GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy.
Topics: Epilepsy; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Intellectual Disability; Nervous System Mal | 2022 |
Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Case-Control St | 2023 |
Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism.
Topics: Amino Acid Sequence; Animals; Autistic Disorder; Cell Line; Child; Electroencephalography; Endoplasm | 2020 |
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |
Neurodevelopmental phenotypes associated with pathogenic variants in
Topics: Autism Spectrum Disorder; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Humans; | 2022 |
Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons.
Topics: Astrocytes; Databases, Factual; Epilepsy; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyri | 2021 |
Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior.
Topics: Animals; Behavior, Animal; Cell Movement; Cerebral Cortex; Endothelial Cells; Female; GABAergic Neur | 2018 |
Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1 syndrome.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Forkhead Transcription Factors; gamma-Aminobu | 2019 |